269 related articles for article (PubMed ID: 19361546)
61. Anti-PEG IgM production induced by PEGylated liposomes as a function of administration route.
Takata H; Shimizu T; Yamade R; Elsadek NE; Emam SE; Ando H; Ishima Y; Ishida T
J Control Release; 2023 Aug; 360():285-292. PubMed ID: 37355210
[TBL] [Abstract][Full Text] [Related]
62. The effect of polymer backbone chemistry on the induction of the accelerated blood clearance in polymer modified liposomes.
Kierstead PH; Okochi H; Venditto VJ; Chuong TC; Kivimae S; Fréchet JMJ; Szoka FC
J Control Release; 2015 Sep; 213():1-9. PubMed ID: 26093095
[TBL] [Abstract][Full Text] [Related]
63. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage.
Abu Lila AS; Kiwada H; Ishida T
J Control Release; 2013 Nov; 172(1):38-47. PubMed ID: 23933235
[TBL] [Abstract][Full Text] [Related]
64. Elucidating the encapsulation of short interfering RNA in PEGylated cationic liposomes.
Buyens K; Demeester J; De Smedt SS; Sanders NN
Langmuir; 2009 May; 25(9):4886-91. PubMed ID: 19341292
[TBL] [Abstract][Full Text] [Related]
65. Influence of phospholipid types and animal models on the accelerated blood clearance phenomenon of PEGylated liposomes upon repeated injection.
Xu H; Ye F; Hu M; Yin P; Zhang W; Li Y; Yu X; Deng Y
Drug Deliv; 2015; 22(5):598-607. PubMed ID: 24524364
[TBL] [Abstract][Full Text] [Related]
66. Reactivity of IgM antibodies elicited by PEGylated liposomes or PEGylated lipoplexes against auto and foreign antigens.
Ando H; Abu Lila AS; Kawanishi M; Shimizu T; Okuhira K; Ishima Y; Ishida T
J Control Release; 2018 Jan; 270():114-119. PubMed ID: 29217175
[TBL] [Abstract][Full Text] [Related]
67. Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo.
Hatakeyama H; Akita H; Maruyama K; Suhara T; Harashima H
Int J Pharm; 2004 Aug; 281(1-2):25-33. PubMed ID: 15288340
[TBL] [Abstract][Full Text] [Related]
68. A mouse model for studying the effect of blood anti-PEG IgMs levels on the in vivo fate of PEGylated liposomes.
El Sayed MM; Shimizu T; Abu Lila AS; Elsadek NE; Emam SE; Alaaeldin E; Kamal A; Sarhan HA; Ando H; Ishima Y; Ishida T
Int J Pharm; 2022 Mar; 615():121539. PubMed ID: 35124114
[TBL] [Abstract][Full Text] [Related]
69. Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response.
Shimizu T; Ichihara M; Yoshioka Y; Ishida T; Nakagawa S; Kiwada H
Biol Pharm Bull; 2012; 35(8):1336-42. PubMed ID: 22863934
[TBL] [Abstract][Full Text] [Related]
70. Time Interval of Two Injections and First-Dose Dependent of Accelerated Blood Clearance Phenomenon Induced by PEGylated Liposomal Gambogenic Acid: The Contribution of PEG-Specific IgM.
Wang F; Ye X; Wu Y; Wang H; Sheng C; Peng D; Chen W
J Pharm Sci; 2019 Jan; 108(1):641-651. PubMed ID: 30595169
[TBL] [Abstract][Full Text] [Related]
71. Enhanced endosomal/lysosomal escape by distearoyl phosphoethanolamine-polycarboxybetaine lipid for systemic delivery of siRNA.
Li Y; Cheng Q; Jiang Q; Huang Y; Liu H; Zhao Y; Cao W; Ma G; Dai F; Liang X; Liang Z; Zhang X
J Control Release; 2014 Feb; 176():104-14. PubMed ID: 24365128
[TBL] [Abstract][Full Text] [Related]
72. Comparative in vivo study of poly(ethylene imine)/siRNA complexes for pulmonary delivery in mice.
Beyerle A; Braun A; Merkel O; Koch F; Kissel T; Stoeger T
J Control Release; 2011 Apr; 151(1):51-6. PubMed ID: 21223987
[TBL] [Abstract][Full Text] [Related]
73. A higher dose of PEGylated gold nanoparticles reduces the accelerated blood clearance phenomenon effect and induces spleen B lymphocytes in albino mice.
Abu-Dief AM; Alsehli M; Awaad A
Histochem Cell Biol; 2022 Jun; 157(6):641-656. PubMed ID: 35157114
[TBL] [Abstract][Full Text] [Related]
74. Pegfilgrastim (PEG-G-CSF) induces anti-PEG IgM in a dose dependent manner and causes the accelerated blood clearance (ABC) phenomenon upon repeated administration in mice.
Elsadek NE; Lila ASA; Emam SE; Shimizu T; Takata H; Ando H; Ishima Y; Ishida T
Eur J Pharm Biopharm; 2020 Jul; 152():56-62. PubMed ID: 32376372
[TBL] [Abstract][Full Text] [Related]
75. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome.
Suzuki R; Takizawa T; Kuwata Y; Mutoh M; Ishiguro N; Utoguchi N; Shinohara A; Eriguchi M; Yanagie H; Maruyama K
Int J Pharm; 2008 Jan; 346(1-2):143-50. PubMed ID: 17640835
[TBL] [Abstract][Full Text] [Related]
76. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.
Ogawara K; Un K; Tanaka K; Higaki K; Kimura T
J Control Release; 2009 Jan; 133(1):4-10. PubMed ID: 18840484
[TBL] [Abstract][Full Text] [Related]
77. Cellular and serological changes in the peripheral blood of splenectomized and spleen autotransplanted mice.
Sipka S; Bráth E; Tóth FF; Aleksza M; Kulcsár A; Fábián A; Baráth S; Balogh P; Sipka S; Furka I; Mikó I
Transpl Immunol; 2006 Aug; 16(2):99-104. PubMed ID: 16860712
[TBL] [Abstract][Full Text] [Related]
78. Repeated injections of PEG-PE liposomes generate anti-PEG antibodies.
Sroda K; Rydlewski J; Langner M; Kozubek A; Grzybek M; Sikorski AF
Cell Mol Biol Lett; 2005; 10(1):37-47. PubMed ID: 15809678
[TBL] [Abstract][Full Text] [Related]
79. Accelerated blood clearance of pegylated liposomal topotecan: influence of polyethylene glycol grafting density and animal species.
Li C; Cao J; Wang Y; Zhao X; Deng C; Wei N; Yang J; Cui J
J Pharm Sci; 2012 Oct; 101(10):3864-76. PubMed ID: 22777607
[TBL] [Abstract][Full Text] [Related]
80. Influence of dose and animal species on accelerated blood clearance of PEGylated liposomal doxorubicin.
Suzuki T; Ichihara M; Hyodo K; Yamamoto E; Ishida T; Kiwada H; Kikuchi H; Ishihara H
Int J Pharm; 2014 Dec; 476(1-2):205-12. PubMed ID: 25280884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
